UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/810,898	03/29/2004	Kazuhiro Ohkouchi	2004_0494	1097
	7590 07/30/200 , LIND & PONACK, I	EXAMINER		
2033 K STREET N. W.			VENKAT, JYOTHSNA A	
SUITE 800 WASHINGTON, DC 20006-1021			ART UNIT	PAPER NUMBER
			1615	
			MAIL DATE	DELIVERY MODE
			07/30/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/810,898	OHKOUCHI ET AL.			
Office Action Summary	Examiner	Art Unit			
	JYOTHSNA A. VENKAT	1615			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on 29 Ag This action is FINAL . 2b) ☑ This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) Claim(s) 12,13 and 33-45 is/are pending in the 4a) Of the above claim(s) is/are withdrav 5) Claim(s) is/are allowed. 6) Claim(s) 12,13 and 33-45 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or Application Papers 9) The specification is objected to by the Examine	vn from consideration.				
10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the confidence of Replacement drawing sheet(s) including the correction of the original transfer of the confidence of the confid	epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). lected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 2/22/08.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	nte			

Art Unit: 1615

DETAILED ACTION

Receipt is acknowledged of amednment, remarks and IDS filed on 4/29/08 and 2/22/08. Claims 40-45 have been added as per applicants' amendment dated 4/29/08. Claims 12-13 and 33-45 are pending in the application.

In view of the amendment the 103 rejection is modified since WO 98/46215 does not teach the claimed active ingredients.

Claim Rejections - 35 USC § 112

Claim 34-36 and 40-42 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is new matter rejection.

There is no support in the specification for mean particle diameter of the saccharide or sugar alcohol is between 35 to 200 microns or 43-300 microns. The support in the specification is for 30-300 microns at page 6, 5-90 microns or 90-500 microns at page 7, 30-90 microns or 30-300 microns or 35-80 microns or 90-300 microns or 90-200 microns at page 8 and specific micron value for each saccharide or sugar alcohol in the examples. Applicants' have not contemplated the range claimed in claims 34-36 and 40-42.

Claim Rejections - 35 USC § 103

Claims 12-13 and 33-45 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combination of WO 98/46215 ('215) and WO 98/53798 ('798).

Art Unit: 1615

The instant application is claiming a quickly disintegrating solid preparation comprising:

a. an active ingredient

- b. Sugar alcohol or saccharide (with a mean particle diameter of 30-300 microns
- c. Disintegrating agent (carmellose calcium, carboxymethylstarch sodium, croscarmellose sodium or crosspovidone)

d. Cellulose compound (crystalline cellulose, powder cellulose, low substituted hydroxyl propyl cellulose or carmellose)

WO '215 teaches all the claimed ingredients in rapidly dissolving dosage form. See the abstract, see pages 4-5, see pages 7-9 for the active ingredients, and see page 17, lines 13-26 for claimed b. The mean particle taught by the document is within the claimed range. See paragraph bridging pages 17-18 for the various saccharide or sugar alcohols. See page 25 for wicking agent. Some of the agents are the species claimed under c as well as d. See the same page, lines 13-20 for povidone of claimed d. See examples 5, 7, and 10 teaches using both c and d in the compositions. WO '215 also discloses that the tablets are made using direct compression wherein the material were weighed and blended (page 29, line 4-5). WO '215 does not teach the active ingredients claimed in the instant application. However WO '798 teaches rapidly disintegrating tablets comprising (a) an active ingredient (2) one or more water soluble sugar alcohol such as maltitol, erythritol and xylitol at page 9, 11 1-25, low-substituted hydroxy propylcellulose at page 9, line 26 through page 10, line 16 and additives such as binders, for example hydroxy propylcellulose, crystalline cellulose and disintegrators for example crosspovidone, croscarmellose sodium, carmellose calcium at page 11, lines 3-7. Additionally WO '798 teaches the active agent can be hypertensive agents such as candersartan cilexetil at page at page 6, lines

Art Unit: 1615

5-6 and anti diabetic agents such as claimed voglibose and pioglitazone hydrochloride at page 6, ll 34-35 and claim 8.

Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to prepare rapidly dosage preparations using all the ingredients of WO '215document and substitute the active ingredient of WO '215 with claimed active ingredients taught by WO '798 in rapidly dissolving solid preparations. One of ordinary skill in the art would have reasonable expectation of success that the claimed dosage form with ingredients would also dissolve rapidly since using ingredient c helps in transport moisture into the dosage form, and the use of ingredient b helps in the production of a hard, non-friable, directly compressible and rapidly dissolvable in-mouth dosage form. Both WO '215 and WO '798 teach rapidly disintegrating solid preparations. It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose. The idea of combining them flows logically from their having been individually taught in the prior art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to JYOTHSNA A. VENKAT whose telephone number is 571-272-0607. The examiner can normally be reached on Monday-Friday, 10:30-7:30:1st Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, MICHAEL WOODWARD can be reached on 571-272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/JYOTHSNA A VENKAT / Primary Examiner, Art Unit 1615